HRP20191396T1 - Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze - Google Patents
Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze Download PDFInfo
- Publication number
- HRP20191396T1 HRP20191396T1 HRP20191396T HRP20191396T1 HR P20191396 T1 HRP20191396 T1 HR P20191396T1 HR P20191396 T HRP20191396 T HR P20191396T HR P20191396 T1 HRP20191396 T1 HR P20191396T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrazol
- tautomer
- stereoisomer
- solvate
- salt
- Prior art date
Links
- BAHVJMJZUDCTPT-UHFFFAOYSA-N 4-quinolin-2-ylimidazol-2-one Chemical class O=C1N=CC(C=2N=C3C=CC=CC3=CC=2)=N1 BAHVJMJZUDCTPT-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- -1 3-difluoromethoxy-5-fluoropyridin-4-yl Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 102000010583 ATR Human genes 0.000 claims 4
- 101000904787 Homo sapiens Serine/threonine-protein kinase ATR Proteins 0.000 claims 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 4
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 4
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 4
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims 4
- 229960001220 amsacrine Drugs 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229960004679 doxorubicin Drugs 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229960004961 mechlorethamine Drugs 0.000 claims 4
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 3
- LWDBMUAJGMXQAY-GSEQGPDBSA-L (1r,2r)-cyclohexane-1,2-diamine;platinum(2+);tetradecanoate;hydrate Chemical compound O.[Pt+2].N[C@@H]1CCCC[C@H]1N.CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O LWDBMUAJGMXQAY-GSEQGPDBSA-L 0.000 claims 2
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 claims 2
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2s,3r,4s,5s,6r)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 2
- PVCULFYROUOVGJ-UHFFFAOYSA-N 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea Chemical compound CNC(=O)N(S(C)(=O)=O)N(S(C)(=O)=O)CCCl PVCULFYROUOVGJ-UHFFFAOYSA-N 0.000 claims 2
- CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 2
- MXPOCMVWFLDDLZ-NSCUHMNNSA-N Apaziquone Chemical compound CN1C(\C=C\CO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-NSCUHMNNSA-N 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 108010092160 Dactinomycin Proteins 0.000 claims 2
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 2
- BKCJZNIZRWYHBN-UHFFFAOYSA-N Isophosphamide mustard Chemical compound ClCCNP(=O)(O)NCCCl BKCJZNIZRWYHBN-UHFFFAOYSA-N 0.000 claims 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 2
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 claims 2
- 108010057150 Peplomycin Proteins 0.000 claims 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims 2
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 2
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 claims 2
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 claims 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims 2
- 229960004176 aclarubicin Drugs 0.000 claims 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229960000473 altretamine Drugs 0.000 claims 2
- 229960002550 amrubicin Drugs 0.000 claims 2
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 2
- 229950002465 apaziquone Drugs 0.000 claims 2
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960002707 bendamustine Drugs 0.000 claims 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 2
- 229950008548 bisantrene Drugs 0.000 claims 2
- 229960001561 bleomycin Drugs 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- 229960002092 busulfan Drugs 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960002115 carboquone Drugs 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 claims 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 2
- 229960004630 chlorambucil Drugs 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 2
- 229960000928 clofarabine Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960003901 dacarbazine Drugs 0.000 claims 2
- 229960000640 dactinomycin Drugs 0.000 claims 2
- 229960003603 decitabine Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- 229960004783 fotemustine Drugs 0.000 claims 2
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 claims 2
- 229950011595 glufosfamide Drugs 0.000 claims 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims 2
- 229960000908 idarubicin Drugs 0.000 claims 2
- 229960001101 ifosfamide Drugs 0.000 claims 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 2
- 229950008097 improsulfan Drugs 0.000 claims 2
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229950000340 laromustine Drugs 0.000 claims 2
- 229960001614 levamisole Drugs 0.000 claims 2
- 229950008991 lobaplatin Drugs 0.000 claims 2
- 229960002247 lomustine Drugs 0.000 claims 2
- 229960001924 melphalan Drugs 0.000 claims 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 2
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 claims 2
- 229960003775 miltefosine Drugs 0.000 claims 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 2
- 229960005485 mitobronitol Drugs 0.000 claims 2
- 229950010913 mitolactol Drugs 0.000 claims 2
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- 229960001156 mitoxantrone Drugs 0.000 claims 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 2
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 claims 2
- 229950007221 nedaplatin Drugs 0.000 claims 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 claims 2
- 229960001420 nimustine Drugs 0.000 claims 2
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 2
- 229960000572 olaparib Drugs 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229950000755 palifosfamide Drugs 0.000 claims 2
- 229950003180 peplomycin Drugs 0.000 claims 2
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 claims 2
- 229950005566 picoplatin Drugs 0.000 claims 2
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims 2
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 claims 2
- 229960000952 pipobroman Drugs 0.000 claims 2
- 229960001221 pirarubicin Drugs 0.000 claims 2
- 229960004403 pixantrone Drugs 0.000 claims 2
- PEZPMAYDXJQYRV-UHFFFAOYSA-N pixantrone Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 claims 2
- 150000003058 platinum compounds Chemical class 0.000 claims 2
- 229960003171 plicamycin Drugs 0.000 claims 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 2
- 229960000624 procarbazine Drugs 0.000 claims 2
- 229960002185 ranimustine Drugs 0.000 claims 2
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 claims 2
- 229960000460 razoxane Drugs 0.000 claims 2
- 229960003452 romidepsin Drugs 0.000 claims 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims 2
- 108010091666 romidepsin Proteins 0.000 claims 2
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims 2
- 229950004707 rucaparib Drugs 0.000 claims 2
- 229960005399 satraplatin Drugs 0.000 claims 2
- 190014017285 satraplatin Chemical compound 0.000 claims 2
- 229960001052 streptozocin Drugs 0.000 claims 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 2
- 229950004550 talazoparib Drugs 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 229960001196 thiotepa Drugs 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims 2
- 229960000977 trabectedin Drugs 0.000 claims 2
- 229960003181 treosulfan Drugs 0.000 claims 2
- 229960000875 trofosfamide Drugs 0.000 claims 2
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 claims 2
- 229960001055 uracil mustard Drugs 0.000 claims 2
- 229960000653 valrubicin Drugs 0.000 claims 2
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 2
- 229950011257 veliparib Drugs 0.000 claims 2
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims 2
- 229950009268 zinostatin Drugs 0.000 claims 2
- 229960000641 zorubicin Drugs 0.000 claims 2
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000035474 group of disease Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (15)
1. Spoj s formulom (IV)
gdje
Het1 je pirazolil, koji može biti nesupstituiran ili mono-, di- ili trisupstituiran, neovisno jedan od drugoga sa Hal ili A,
A u svakom slučaju neovisno označava nerazgranati ili razgranati alkil koji ima 1, 2, 3, 4, 5 ili 6 C atoma, gdje, međusobno neovisno, 1, 2, 3, 4, ili 5 H atoma mogu biti zamijenjeni s Hal,
Hal predstavlja F, Cl, Br ili I,
HET je odabran od: 3-difluorometoksi-5-fluoropiridin-4-il, 3-fluoro-5-metoksipiridin-4-il, 3-fluoro-5-fluorometoksipiridin-4-il, 3-fluoro-5-(trideuteriometoksi)piridin-4-il,
i/ili njihovog farmaceutski upotrebljivog derivata, soli, solvata, tautomera, stereoizomera.
2. Spoj s formulom (IV) prema zahtjevu 1, naznačen time što je Het1 odabran iz niza koji sadrži: 1H-pirazol-4-il, 2H-pirazol-3-il, 1H-pirazol-3-il, 1-metil-1H-pirazol-4-il, 3-metil-1H-pirazol-4-il, 5-metil-1H-pirazol-3-il, 4-metil-1H-pirazol-3-il, 1-fluorometil-1H-pirazol-4-il, 1-difluorometil-1H-pirazol-4-il, 1,3-dimetil-1H-pirazol-4-il, 1-etil-1H-pirazol-4-il, 1-etil-3-metil-1H-pirazolil, 3-fluoro-1-metil-1H-pirazol-4-il,
i/ili njihov farmaceutski upotrebljiv derivat, sol, solvat, tautomer, stereoizomer.
3. Spoj prema zahtjevu 1, naznačen time što je odabran od
i/ili njegov farmaceutski upotrebljiv derivat, sol, solvat, tautomer, stereoizomer.
4. Spoj prema jednom od zahtjeva 1 do 3 i/ili njegov farmaceutski upotrebljiv derivat, sol, solvat, tautomer ili stereoizomer, naznačen time što je za uporabu kao lijek.
5. Spoj prema jednom od zahtjeva 1 do 3 i/ili njegov farmaceutski upotrebljiv derivat, sol, solvat, tautomer ili stereoizomer, naznačen time što je za uporabu u liječenju raka, tumora i/ili metastaza.
6. Spoj prema jednom od zahtjeva 1 do 3 i/ili njegov farmaceutski upotrebljiv derivat, sol, solvat, tautomer, stereoizomer, naznačen time što je za uporabu u liječenju raka, tumora i/ili metastaza u kombinaciji s radioterapijom.
7. Spoj prema jednom od zahtjeva 1 do 3 i/ili njegov farmaceutski upotrebljiv derivat, sol, solvat, tautomer, stereoizomer naznačen time što je za uporabu u liječenju raka, tumora i/ili metastaza u kombinaciji s najmanje jednim antikancerogenim sredstvom.
8. Spoj i/ili njegov farmaceutski upotrebljiv derivat, sol, solvat, tautomer, stereoizomer za uporabu prema jednom od patentnih zahtjeva 5 do 7 naznačen time što je tumor odabran iz skupine bolesti skvamoznog epitela, mjehura, želuca, bubrega, glave, vrata, jednjaka, grlića maternice, štitnjače, crijeva, kosti, jetre, mozga, prostate, urogenitalnog trakta, limfnog sustava, grkljana, pluća, kože, krvi i imunološkog sustava, i/ili rak je odabran iz skupine koju čine monocitna leukemija, adenokarcinom pluća, karcinom pluća malih stanica, rak gušterače, glioblastom, karcinom crijeva, karcinom dojke, akutna mijeloična leukemija, kronična mijeloična leukemija, akutna limfatična leukemija, kronična limfatična leukemija, Hodgkinov limfom i ne-Hodgkinov limfom.
9. Farmaceutski pripravak naznačen time što sadrži učinkovitu količinu najmanje jednog spoja prema jednom od zahtjeva 1 do 3 i/ili njegov farmaceutski upotrebljiv derivat, sol, solvat, tautomer ili stereoizomer, po izboru zajedno s najmanje jednom farmaceutski podnošljivom pomoćnom tvari.
10. Farmaceutski pripravak prema zahtjevu 9, naznačen time što nadalje sadrži najmanje jedno antikancerogeno sredstvo.
11. Komplet naznačen time što sadrži zasebna pakiranja
(a) učinkovite količine spoja prema jednom od zahtjeva 1 do 3 i/ili njegov farmaceutski upotrebljiv derivat, sol, solvat, tautomer ili stereoizomer, i
(b) učinkovite količine daljnjeg antikancernog sredstva.
12. Farmaceutski pripravak prema zahtjevu 10, naznačen time što je najmanje jedno antikancerogeno sredstvo odabrano od sredstava za alkiliranje, spojeva platine, inhibitora topoizomeraze, inhibitora poli-(ADP-riboza)-polimeraze (PARP), inhibitora ATR (ataksija telangiektazija i Rad3 povezanih), antikancerogenih antibiotika i alfa emitera.
13. Farmaceutski pripravak prema zahtjevu 10, naznačen time što je najmanje jedno antikancerogeno sredstvo odabrano iz skupa koji sadrži altretamin, bendamustin, busulfan, karmustin, klorambucil, klormetin, ciklofosfamid, dakarbazin, ifosfamid, improsulfan tozilat, lomustin, melfalan, mitobronitol, mitolaktol, nimustin, ranimustin, temozolomid, tiotepa, treosulfan, mekloretamin, karbokvon, apazikuon, fotemustin, glufosfamid, palifosfamid, pipobroman, trofosfamid, uramustin; karboplatin, cisplatin, eptaplatin, miriplatin hidrat, oksaliplatin, lobaplatin, nedaplatin, pikoplatin, satraplatin; etopozid, irinotekan, razoksan, sobuzoksan, topotekan, kamptotecin, doksorubicin, amsakrin; talazoparib, olaparib, veliparib, rukaparib, CEP 9722, MK4827, BGB-290; VE-822, AZ20, AZD6738; amrubicin, bisantren, decitabin, mitoksantron, prokarbazin, trabektedin, klofarabin, amsakrin, brostalicin, piksantron, laromustin; bleomicin, daktinomicin, doksorubicin, epirubicin, idarubicin, levamizol, miltefozin, mitomicin C, romidepsin, streptozocin, valrubicin, zinostatin, zorubicin, daunurobicin, plikamicin, aklarubicin, peplomicin, pirarubicin.
14. Komplet prema zahtjevu 11, naznačen time što je daljnje antikancerogeno sredstvo odabrano od sredstava za alkiliranje, spojeva platine, inhibitora topoizomeraze, inhibitora poli-(ADP-riboza)-polimeraze (PARP), inhibitora ATR (ataksija telangiektazija i Rad3 povezanih), antikancerogenih antibiotika i alfa emitera.
15. Komplet prema zahtjevu 11, naznačen time što je najmanje jedno antikancerogeno sredstvo odabrano iz skupa koji sadrži altretamin, bendamustin, busulfan, karmustin, klorambucil, klormetin, ciklofosfamid, dakarbazin, ifosfamid, improsulfan tozilat, lomustin, melfalan, mitobronitol, mitolaktol, nimustin, ranimustin, temozolomid, tiotepa, treosulfan, mekloretamin, karbokvon, apazikuon, fotemustin, glufosfamid, palifosfamid, pipobroman, trofosfamid, uramustin; karboplatin, cisplatin, eptaplatin, miriplatin hidrat, oksaliplatin, lobaplatin, nedaplatin, pikoplatin, satraplatin; etopozid, irinotekan, razoksan, sobuzoksan, topotekan, kamptotecin, doksorubicin, amsakrin; talazoparib, olaparib, veliparib, rukaparib, CEP 9722, MK4827, BGB-290; VE-822, AZ20, AZD6738; amrubicin, bisantren, decitabin, mitoksantron, prokarbazin, trabektedin, klofarabin, amsakrin, brostalicin, piksantron, laromustin; bleomicin, daktinomicin, doksorubicin, epirubicin, idarubicin, levamizol, miltefozin, mitomicin C, romidepsin, streptozocin, valrubicin, zinostatin, zorubicin, daunurobicin, plikamicin, aklarubicin, peplomicin, pirarubicin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15000968 | 2015-04-02 | ||
EP16717560.3A EP3277681B1 (de) | 2015-04-02 | 2016-03-31 | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
PCT/EP2016/000542 WO2016155884A1 (de) | 2015-04-02 | 2016-03-31 | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191396T1 true HRP20191396T1 (hr) | 2019-11-01 |
Family
ID=52814780
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191396 HRP20191396T1 (hr) | 2015-04-02 | 2019-08-01 | Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze |
HRP20210981TT HRP20210981T1 (hr) | 2015-04-02 | 2021-06-23 | Imidazolonil kinolini i njihova uporaba kao inhibitori atm kinaze |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210981TT HRP20210981T1 (hr) | 2015-04-02 | 2021-06-23 | Imidazolonil kinolini i njihova uporaba kao inhibitori atm kinaze |
Country Status (24)
Country | Link |
---|---|
US (5) | US10457677B2 (hr) |
EP (3) | EP3868761B1 (hr) |
JP (2) | JP6791873B2 (hr) |
KR (2) | KR102652052B1 (hr) |
CN (3) | CN107889488B (hr) |
AU (3) | AU2016239270B2 (hr) |
BR (1) | BR122019005502B1 (hr) |
CA (1) | CA2981365A1 (hr) |
DK (2) | DK3560924T3 (hr) |
ES (3) | ES2741853T3 (hr) |
HR (2) | HRP20191396T1 (hr) |
HU (2) | HUE045477T2 (hr) |
IL (3) | IL254714B (hr) |
LT (2) | LT3560924T (hr) |
MX (2) | MX2017012613A (hr) |
PL (2) | PL3277681T3 (hr) |
PT (2) | PT3560924T (hr) |
RS (2) | RS62082B1 (hr) |
RU (1) | RU2743343C2 (hr) |
SG (2) | SG10202002181UA (hr) |
SI (2) | SI3277681T1 (hr) |
TR (1) | TR201911244T4 (hr) |
WO (1) | WO2016155884A1 (hr) |
ZA (1) | ZA201707423B (hr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2981365A1 (en) * | 2015-04-02 | 2016-10-06 | Merck Patent Gmbh | Imidazolonylquinolines and the use thereof as atm kinase inhibitors |
GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
CN110312717B (zh) * | 2017-02-27 | 2022-04-12 | 上海瑛派药业有限公司 | 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用 |
JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
AU2019208024A1 (en) | 2018-01-12 | 2020-08-13 | Prolynx Llc | Protocol for minimizing toxicity of combination dosages and imaging agent for verification |
CA3093499A1 (en) * | 2018-03-14 | 2019-09-19 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
KR20200143367A (ko) | 2018-04-12 | 2020-12-23 | 바이엘 악티엔게젤샤프트 | 살충제로서의 n-(시클로프로필메틸)-5-(메틸술포닐)-n-{1-[1-(피리미딘-2-일)-1h-1,2,4-트리아졸-5-일]에틸}벤즈아미드 유도체 및 상응하는 피리딘-카르복스아미드 유도체 |
WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
GB201814487D0 (en) * | 2018-09-06 | 2018-10-24 | Cycle Pharmaceuticals Ltd | Cancer |
CN109045042A (zh) * | 2018-09-21 | 2018-12-21 | 上海交通大学医学院附属上海儿童医学中心 | Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用 |
CN112771045B (zh) * | 2018-09-30 | 2022-04-19 | 南京明德新药研发有限公司 | 喹啉并吡咯烷-2-酮类衍生物及其应用 |
AU2020247451A1 (en) | 2019-03-27 | 2021-11-18 | Merck Patent Gmbh | Imidazolonylquinoline compounds and therapeutic uses thereof |
BR112022001067A2 (pt) * | 2019-07-30 | 2022-05-24 | Xrad Therapeutics Inc | Inibidores duplos de atm e dna-pk para uso em terapia antitumoral |
WO2021084124A1 (en) | 2019-11-01 | 2021-05-06 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
EP4069366A1 (en) * | 2019-12-04 | 2022-10-12 | CHDI Foundation, Inc. | Atm kinase inhibitors and compositions and methods of use thereof |
CN115003672A (zh) * | 2020-01-09 | 2022-09-02 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
WO2021197339A1 (zh) * | 2020-03-30 | 2021-10-07 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
IL299178A (en) * | 2020-06-18 | 2023-02-01 | Merck Patent Gmbh | ATM inhibitors for use in the treatment of viral infections |
EP4171651A1 (en) | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atm inhibitor |
US20230330027A1 (en) | 2020-09-18 | 2023-10-19 | Merck Patent Gmbh | Pharmaceutical preparation |
CN116056698A (zh) | 2020-09-21 | 2023-05-02 | 钟卫 | 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物 |
EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
BRPI0609399A2 (pt) * | 2005-03-21 | 2010-03-30 | Ferrer Int | método para produzir compostos da 1h-imidazo[4,5-c]quinolin-4-amina 1-substituìda e intermediários dos mesmos |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
KR101472607B1 (ko) | 2007-02-20 | 2014-12-15 | 노파르티스 아게 | 지질 키나제 및 mTOR의 이중 억제제로서의 이미다조퀴놀린 |
BRPI0909082A2 (pt) | 2008-03-26 | 2019-02-26 | Novartis Ag | imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf |
HUE028347T2 (en) | 2008-06-10 | 2016-12-28 | Abbvie Inc | Tricyclic compounds |
CA2738868C (en) | 2008-10-01 | 2017-01-17 | Novartis Ag | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
JP2012528829A (ja) | 2009-06-04 | 2012-11-15 | ノバルティス アーゲー | 1H−イミダゾ[4,5−c]キノリノン化合物 |
UA106074C2 (uk) * | 2009-06-04 | 2014-07-25 | Новартіс Аг | ПОХІДНІ 1H-ІМІДАЗО[4,5-c]ХІНОЛІНОНУ |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
CN102803227B (zh) * | 2010-03-16 | 2016-01-20 | 默克专利有限公司 | 吗啉基喹唑啉 |
ES2792799T3 (es) * | 2010-06-28 | 2020-11-12 | Merck Patent Gmbh | [1,8]naftiridinas 2,4-diaril-sustituidas como inhibidores de quinasas para su uso contra el cáncer |
CN102372711B (zh) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药(上海)有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
MX2013006187A (es) | 2010-12-03 | 2013-07-15 | Novartis Ag | Composiciones farmaceuticas. |
CN103012398B (zh) | 2011-09-19 | 2015-10-14 | 上海恒瑞医药有限公司 | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
US9879003B2 (en) | 2012-04-11 | 2018-01-30 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
BR112014030099A2 (pt) | 2012-06-06 | 2017-06-27 | Novartis Ag | combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor |
NO2714752T3 (hr) * | 2014-05-08 | 2018-04-21 | ||
CA2981365A1 (en) | 2015-04-02 | 2016-10-06 | Merck Patent Gmbh | Imidazolonylquinolines and the use thereof as atm kinase inhibitors |
-
2016
- 2016-03-31 CA CA2981365A patent/CA2981365A1/en active Pending
- 2016-03-31 CN CN201680031887.8A patent/CN107889488B/zh active Active
- 2016-03-31 SI SI201630345T patent/SI3277681T1/sl unknown
- 2016-03-31 PL PL16717560T patent/PL3277681T3/pl unknown
- 2016-03-31 LT LTEP19172903.7T patent/LT3560924T/lt unknown
- 2016-03-31 US US15/563,680 patent/US10457677B2/en active Active
- 2016-03-31 MX MX2017012613A patent/MX2017012613A/es active IP Right Grant
- 2016-03-31 TR TR2019/11244T patent/TR201911244T4/tr unknown
- 2016-03-31 RU RU2017138100A patent/RU2743343C2/ru active
- 2016-03-31 BR BR122019005502-5A patent/BR122019005502B1/pt active IP Right Grant
- 2016-03-31 RS RS20210817A patent/RS62082B1/sr unknown
- 2016-03-31 WO PCT/EP2016/000542 patent/WO2016155884A1/de active Application Filing
- 2016-03-31 JP JP2017551589A patent/JP6791873B2/ja active Active
- 2016-03-31 EP EP21165573.3A patent/EP3868761B1/de active Active
- 2016-03-31 CN CN202010644109.4A patent/CN111747952A/zh active Pending
- 2016-03-31 KR KR1020177031770A patent/KR102652052B1/ko active IP Right Grant
- 2016-03-31 DK DK19172903.7T patent/DK3560924T3/da active
- 2016-03-31 PL PL19172903T patent/PL3560924T3/pl unknown
- 2016-03-31 DK DK16717560.3T patent/DK3277681T3/da active
- 2016-03-31 AU AU2016239270A patent/AU2016239270B2/en active Active
- 2016-03-31 SG SG10202002181UA patent/SG10202002181UA/en unknown
- 2016-03-31 RS RS20190993A patent/RS59139B1/sr unknown
- 2016-03-31 PT PT191729037T patent/PT3560924T/pt unknown
- 2016-03-31 EP EP16717560.3A patent/EP3277681B1/de active Active
- 2016-03-31 HU HUE16717560A patent/HUE045477T2/hu unknown
- 2016-03-31 PT PT16717560T patent/PT3277681T/pt unknown
- 2016-03-31 ES ES16717560T patent/ES2741853T3/es active Active
- 2016-03-31 SG SG11201708065QA patent/SG11201708065QA/en unknown
- 2016-03-31 CN CN202010644289.6A patent/CN111689963A/zh active Pending
- 2016-03-31 SI SI201631240T patent/SI3560924T1/sl unknown
- 2016-03-31 KR KR1020247009513A patent/KR20240044525A/ko active Search and Examination
- 2016-03-31 HU HUE19172903A patent/HUE054745T2/hu unknown
- 2016-03-31 MX MX2020011558A patent/MX2020011558A/es unknown
- 2016-03-31 EP EP19172903.7A patent/EP3560924B1/de active Active
- 2016-03-31 ES ES21165573T patent/ES2946507T3/es active Active
- 2016-03-31 LT LTEP16717560.3T patent/LT3277681T/lt unknown
- 2016-03-31 ES ES19172903T patent/ES2880626T3/es active Active
-
2017
- 2017-09-26 IL IL254714A patent/IL254714B/en active IP Right Grant
- 2017-11-01 ZA ZA2017/07423A patent/ZA201707423B/en unknown
-
2019
- 2019-03-14 US US16/353,559 patent/US10745399B2/en active Active
- 2019-08-01 HR HRP20191396 patent/HRP20191396T1/hr unknown
- 2019-12-17 IL IL271494A patent/IL271494B/en active IP Right Grant
-
2020
- 2020-06-24 US US16/910,438 patent/US10975075B2/en active Active
- 2020-06-25 AU AU2020204241A patent/AU2020204241B2/en active Active
- 2020-11-05 JP JP2020185129A patent/JP7111790B2/ja active Active
-
2021
- 2021-03-17 US US17/204,619 patent/US11608338B2/en active Active
- 2021-04-22 IL IL282584A patent/IL282584B/en unknown
- 2021-06-23 HR HRP20210981TT patent/HRP20210981T1/hr unknown
-
2022
- 2022-10-21 AU AU2022256215A patent/AU2022256215A1/en active Pending
-
2023
- 2023-03-01 US US18/116,094 patent/US20230203034A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191396T1 (hr) | Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze | |
JP2018510191A5 (hr) | ||
ES2948949T3 (es) | Inhibidores de la interacción menina-MLL | |
US10500193B2 (en) | Combination therapy of HSP90 inhibitors with platinum-containing agents | |
US20230106592A1 (en) | Method for treating cancer using a combination of dna damaging agents and atr inhibitors | |
RU2011123647A (ru) | Соединения, полезные в качестве ингибиторов atr киназы | |
DK2994467T3 (en) | ARYLCHINAZOLIN | |
UA126177C2 (uk) | Похідні 2-амінопіридину або 2-амінопіримідину як інгібітори циклінзалежної кінази | |
HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
JP2014510151A5 (hr) | ||
HRP20171915T1 (hr) | Spojevi korisni kao inhibitori atr kinaze i kombinirane terapije koje ih koriste | |
ES2629932T3 (es) | Inhibidor de PFKFB3 y métodos de uso como terapéutico contra el cáncer | |
RU2012153675A (ru) | Соединения, пригодные в качестве ингибиторов atr киназы | |
SI2376485T1 (en) | PIRAZINE DERIVATIVES USE AS ATR KINASE INHIBITORS | |
IL257847A (en) | Derivatives of 8– [6– [3 [- (amino) propoxy] –3 – pyridyl] –1 – isopropyl – imidazo [4, 5 –c] quinoline – 2 – ion as selective kinases of kinase atm for cancer treatment | |
AR095308A1 (es) | Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento | |
JP2015515478A5 (hr) | ||
PE20081379A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
Shin et al. | Synergistic effect of immunoliposomal gemcitabine and bevacizumab in glioblastoma stem cell-targeted therapy | |
JP2019501873A5 (hr) | ||
RU2016144668A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
JP2013213055A5 (hr) | ||
Arcaro et al. | Current status of clinical trials for small cell lung cancer | |
JP2013523814A5 (hr) | ||
JP6422936B2 (ja) | 5−ブロモ−インジルビン |